Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy

J Nucl Med. 2004 Sep;45(9):1480-7.

Abstract

We evaluated quantitative measurement series (MS) with 18F-FDG and PET and compared different quantification methods for prediction of individual survival in patients with metastatic colorectal cancer receiving chemotherapy with 5-fluorouracil, folinic acid, and oxaliplatin (FOLFOX).

Methods: The study comprised 25 patients. All patients were examined before the onset of FOLFOX therapy and after completion of the first and fourth cycles. SUV, fractal dimension (FD), a 2-compartment model with computation of k1, k2, k3, and k4, and vascular fraction (VB) were used for data evaluation. Survival data served as a reference for the PET data. Discriminant analysis (DA), regression, and best-subset analysis were applied to the data.

Results: Twenty of 25 patients died up to 801 d after the first PET study. A cutoff of 1 y (364 d) was used to classify the patients into 2 a priori groups, namely the short- and long-term survival groups. DA was used to predict the 2 categories using SUV and kinetic parameters of 18F-FDG metabolism as predictor variables. SUV provided a correct classification rate (CCR) ranging from 62% to 69%. SUV of the third MS resulted in a CCR of 69% as a single parameter. The best results were yielded by the use of kinetic parameters (k1, k3, VB, and FD) as predictor variables. CCR was 78% using kinetic 18F-FDG parameters of the first and third MS, in comparison with 69% for the corresponding SUVs. A multiple linear regression model was applied to the data to assess the relationship between individual survival and the PET data. The best-subset method revealed a correlation coefficient of 0.850 for the kinetic parameters of the first (k3, k4, VB, and FD) and third (k1, k2, k4, and VB) MS.

Conclusion: The combination of kinetic parameters of the first and the third MS is acceptable for classification into a short or long survival class. Furthermore, even an individual prognosis of survival can be achieved using kinetic 18F-FDG parameters of the first and third MS.

Publication types

  • Clinical Trial
  • Comparative Study
  • Validation Study

MeSH terms

  • Algorithms*
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Colorectal Neoplasms / diagnostic imaging*
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / mortality
  • Colorectal Neoplasms / secondary
  • Disease-Free Survival
  • Fluorodeoxyglucose F18*
  • Fluorouracil / administration & dosage*
  • Humans
  • Image Interpretation, Computer-Assisted / methods*
  • Kinetics
  • Leucovorin / administration & dosage*
  • Organoplatinum Compounds
  • Prognosis
  • Radionuclide Imaging
  • Radiopharmaceuticals
  • Reproducibility of Results
  • Risk Assessment / methods*
  • Risk Factors
  • Sensitivity and Specificity
  • Survival Analysis
  • Treatment Outcome

Substances

  • Organoplatinum Compounds
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18
  • Leucovorin
  • Fluorouracil

Supplementary concepts

  • Folfox protocol